Shares of Agile Therapeutics Inc (NASDAQ:AGRX) reached a new 52-week low on Friday . The stock traded as low as $0.25 and last traded at $0.26, with a volume of 2949 shares traded. The stock had previously closed at $0.26.

Several analysts have weighed in on AGRX shares. ValuEngine raised shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Royal Bank of Canada lowered their price target on shares of Agile Therapeutics to $3.00 and set an “outperform” rating for the company in a research note on Monday, May 21st. Finally, HC Wainwright set a $8.00 price target on shares of Agile Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, May 9th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $6.25.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings data on Friday, August 3rd. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01. sell-side analysts forecast that Agile Therapeutics Inc will post -0.61 earnings per share for the current year.

In other news, insider Life Sciences Maste Perceptive sold 298,628 shares of the company’s stock in a transaction dated Thursday, July 26th. The shares were sold at an average price of $0.30, for a total transaction of $89,588.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.30% of the company’s stock.

Large investors have recently modified their holdings of the company. Bank of New York Mellon Corp raised its stake in shares of Agile Therapeutics by 113.1% during the fourth quarter. Bank of New York Mellon Corp now owns 38,920 shares of the specialty pharmaceutical company’s stock valued at $105,000 after acquiring an additional 20,654 shares during the last quarter. A.R.T. Advisors LLC raised its stake in shares of Agile Therapeutics by 82.3% during the first quarter. A.R.T. Advisors LLC now owns 66,426 shares of the specialty pharmaceutical company’s stock valued at $170,000 after acquiring an additional 29,995 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Agile Therapeutics by 62.8% during the first quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after acquiring an additional 55,937 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Agile Therapeutics by 313.7% during the fourth quarter. Renaissance Technologies LLC now owns 366,100 shares of the specialty pharmaceutical company’s stock valued at $985,000 after acquiring an additional 277,600 shares during the last quarter. Finally, Franklin Resources Inc. raised its stake in shares of Agile Therapeutics by 17.0% during the first quarter. Franklin Resources Inc. now owns 3,355,200 shares of the specialty pharmaceutical company’s stock valued at $8,623,000 after acquiring an additional 487,400 shares during the last quarter. 72.41% of the stock is owned by hedge funds and other institutional investors.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Featured Article: Stock Symbols and CUSIP Explained

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.